A Study of TQA3526 in the Treatment of Primary Biliary Cirrhosis (PBC)
A Phase IIa, Randomized, Double-blind, Placebo-controlled Study of TQA3526 in the Treatment of Naive or Previously Treated PBC Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Junqi Niu
- Phone Number: 13756661205
- Email: junqiniu@aliyun.com
Study Locations
-
-
Jilin
-
Changchun, Jilin, China, 130000
- The First Hospital of Jilin University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1.18 and 70 years old, male or female. 2.Proven as PBC, as demonstrated by the patient presenting with at least 2 of the following 3 diagnostic factors:
- History of increased ALP levels for at least 3 months prior to Day 0 in previously treated PBC patients,or ALP levels increased during screening in treatment naive PBC patients; ② Positive AMA titer (>1:40 titer on immunofluorescence or M2 positive by ELISA) or PBC-specific antinuclear antibodies (anti-GP210 and anti-SP100 positive); ③ Liver biopsy consistent with PBC within 24W prior to randomization; 3.ALP value between 1.67 and 10 × ULN; 4.Taking ursodeoxycholic acid (UDCA) for at least 12 months (stable dose for ≥ 3 months) prior to Day 0, or unable to tolerate UDCA (no UDCA for ≥ 3 months) prior to Day 0.
Exclusion Criteria:
- 1.Has other virus infected ; 2.History or presence of other concomitant liver diseases; 3.Presence of clinical complications of PBC or clinically significant hepatic decompensation; 4.Child-pugh grade B or C in patients with cirrhosis; 5.Creatinine (Cr) ≥1.5 times the upper limit of normal value and serum creatinine clearance rate <60mL/min; 6.ALT or AST>5×ULN;TBil>3×ULN; 7.Patients with a history of severe pruritus within 2 months prior to day 0; 8.History or presence of clinically concerning cardiac arrhythmias, the duration of the study may affect survival; 9.Presence of any other disease or condition that is interfering with the absorption, distribution, metabolism, or excretion of drugs including bile salt metabolism in the intestine; 10.Medical conditions that may cause nonhepatic increases in ALP (e.g., Paget's disease) or which may diminish life expectancy to < 2 years.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Climbing group
|
Tablet(s) administered orally once daily
Tablet(s) administered orally once daily
|
|
Experimental: Titration group
|
Tablet(s) administered orally once daily
Tablet(s) administered orally once daily
|
|
Experimental: Extension group
|
Tablet(s) administered orally once daily
Tablet(s) administered orally once daily
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Alkaline phosphatase (ALP)
Time Frame: Baseline up to 24w
|
The reduction of ALP level from baseline to 24 weeks.
|
Baseline up to 24w
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Liver function:ALP (excluding 12W/24W), ALT, AST, GGT, TBA and Tbil
Time Frame: Baseline up to 2, 4, 8, 12, 14, 16, 20, 24 weeks
|
The reduction of ALP , ALT, AST, GGT, TBA and Tbil from baseline to each time point.
|
Baseline up to 2, 4, 8, 12, 14, 16, 20, 24 weeks
|
|
Fasting lipid:LDL-C、HDL-C、TG and TC
Time Frame: Baseline up to 2, 4, 8, 12, 14, 16, 20, 24 weeks
|
The rate of change of LDL-C、HDL-C、TG and TC from baseline to each time point.
|
Baseline up to 2, 4, 8, 12, 14, 16, 20, 24 weeks
|
|
Cmax
Time Frame: predose, Weeks 2, 4, 8, 12, 14, 16, 20, 24 : 0, 1.5, 3.5 hours following drug administration
|
Maximum concentration of the analyte in plasma.
|
predose, Weeks 2, 4, 8, 12, 14, 16, 20, 24 : 0, 1.5, 3.5 hours following drug administration
|
|
tmax
Time Frame: predose, Weeks 2, 4, 8, 12, 14, 16, 20, 24 : 0, 1.5, 3.5 hours following drug administration
|
Time from dosing to maximum concentration
|
predose, Weeks 2, 4, 8, 12, 14, 16, 20, 24 : 0, 1.5, 3.5 hours following drug administration
|
|
AUC0-∞
Time Frame: predose, Weeks 2, 4, 8, 12, 14, 16, 20, 24 : 0, 1.5, 3.5 hours following drug administration
|
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity
|
predose, Weeks 2, 4, 8, 12, 14, 16, 20, 24 : 0, 1.5, 3.5 hours following drug administration
|
|
pharmacodynamics
Time Frame: Baseline up to 2, 4, 8, 12, 14, 16, 20, 24 weeks
|
The rate of change of FGF-19、C4、IgG and IgM from baseline to each time point.
|
Baseline up to 2, 4, 8, 12, 14, 16, 20, 24 weeks
|
|
safety and tolerability: incidence of treatment emergent adverse events and serious treatment emergent adverse events
Time Frame: Baseline up to 2, 4, 8, 12, 14, 16, 20, 24 weeks
|
Evaluate safety and tolerability as assessed by the incidence of treatment emergent adverse events and serious treatment emergent adverse events comparing TQA3526 to placebo.
|
Baseline up to 2, 4, 8, 12, 14, 16, 20, 24 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- TQA3526-Ⅱ-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.